1. Nussey S, Whitehead S. Enocrinology: An Intergrated Approch. 1th ed. Oxford: BIOS Scientific Publishers; 2001. p. 115-68.
3. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-14.
5. Bracken MB, Collins WF, Freeman DF, Shepard MJ, Wagner FW, Silten RM, et al. Efficacy of methylprednisolone in acute spinal cord injury. JAMA 1984;251:45-52.
6. Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinalcord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990;322:1405-11.
7. Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997;277:1597-604.
8. Bracken MB. Steroids for acute spinal cord injury. Cochrane Database Syst Rev 2012;1:CD001046.
9. Ahuja CS, Nori S, Tetreault L, Wilson J, Kwon B, Harrop J, et al. Traumatic spinal cord injury-repair and regeneration. Neurosurgery 2017;80(3S):S9-22.
10. McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain 1987;110(Pt 6):1617-30.
11. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989;46:878-84.
12. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy. Neurology 1993;43:2202-9.
13. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997;48:321-8.
14. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975;50:621-37.
15. Dyck PJ, O'Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982;11:136-41.
16. Mehndiratta MM, Hughes RA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002;(1):CD002062.
17. Brannagan TH 3rd. Current treatments of chronic immunemediated demyelinating polyneuropathies. Muscle Nerve 2009;39:563-78.
18. Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 2005;62:249-54.
19. Muley SA, Kelkar P, Parry GJ. Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Arch Neurol 2008;65:1460-4.
20. Hughes RA, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004;(4):CD003280.
21. Simmons Z. Treatment and Management of Autoimmune Neuropathies. In: Bertorini TE, editor. Neuromuscular Disorders: Treatment and Management. 1st ed. Philadelphia: Saunders; 2011. p. 215-35.
22. van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 2010;9:245-53.
23. Dalakas MC; Medscape. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 2011;7:507-17.
24. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004;50:3408-17.
25. Gorson KC, van Schaik IN, Merkies IS, Lewis RA, Barohn RJ, Koski CL, et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst 2010;15:326-33.
26. Eftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN; PREDICT. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 2012;78:1079-84.
27. Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, Messina P, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 2012;11:493-502.
28. Börü ÜT, Erdoğan H, Alp R, Taşdemir M, Yıldırım S, Bilgiç A, et al. Treatment of chronic inflammatory demyelinating polyneuropathy with high dose intravenous methylprednisolone monthly for five years: 10-year follow up. Clin Neurol Neurosurg 2014;118:89-93.
29. Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pract Neurol 2008;4:317-27.
30. Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand 1998;97:370-3.
31. Howard FM Jr, Duane DD, Lambert EH, Daube JR. Alternateday prednisone: preliminary report of a double-blind controlled study. Ann N Y Acad Sci 1976;274:596-607.
32. Schuchardt V, Kohler W, Hund E, Scheglmann K, Fleisher E, Jung K, et al. A randomized, controlled trial of high-dose intravenous immunoglobulin versus methylprednisolone in moderate exacerbations of myasthenia gravis: final analysis after early termination (unpublished data). Cited in Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR: Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 2015;(2):CD002828.
33. Millikan CH, Eaton LM. Clinical-evaluation of ACTH and cortisone in myasthenia gravis. Neurology 1951;1:145-52.
34. Grob D, Harvey AM. Effect of adrenocorticotropic hormone (ACTH) and cortisone administration in patients with myasthenia gravis and report of onset of myasthenia gravis during prolonged cortisone administration. Bull Johns Hopkins Hosp 1952;91:124-36.
35. Bae JS, Go SM, Kim BJ. Clinical predictors of steroid induced exacerbation in myasthenia gravis. J Clin Neurosci 2006;13:1006-10.
36. Abramsky O, Aharonov A, Teitelbaum D, Fuchs S. Myasthenia gravis and acetylcholine receptor. Effect of steroids in clinical course and cellular immune response to acetylcholine receptor. Arch Neurol 1975;32:684-7.
38. Seybold ME, Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med 1974;290:81-4.
39. Drachman DB. Myasthenia gravis. N Engl J Med 1994;330:1797-810.
41. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010;17:893-902.
42. Miano MA, Bosley TM, Heiman-Patterson TD, Reed J, Sergott RC, Savino PJ, et al. Factors influencing outcome of prednisone dose reduction in myasthenia gravis. Neurology 1991;41:919-21.
43. Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008;71:394-9.
44. Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, et al. An international, phase III, randomized trial of mycophenolate mycophenolate mofetil in myasthenia gravis. Neurology 2008;71:400-6.
45. Yoshikawa H, Kiuchi T, Saida T, Takamori M. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011;82:970-7.
46. Benatar M, Kaminski HJ; Quality Standards Subcommittee of the American Academy of Neurology. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology. Neurology 2007;68:2144-9.
47. Evoli A, Tonali P, Bartoccioni E, Lo Monaco M. Ocular myasthenia: diagnostic and therapeutic problems. Acta Neurol Scand 1988;77:31-5.
48. Mount FW. Corticotropin in treatment of ocular myasthenia; a controlled clinical trial. Arch Neurol 1964;11:114-24.
49. Fisher KC, Schwartzman RJ. Oral corticosteroids in the treatment of ocular myasthenia gravis. Ann N Y Acad Sci 1976;274:652-8.
50. Nakamura H, Taniguchi Y, Suzuki Y, Tanaka Y, Ishiguro K, Fukuda M, et al. Delayed remission after thymectomy for myasthenia gravis of the purely ocular type. J Thorac Cardiovasc Surg 1996;112:371-5.
52. Bhanushali MJ, Wuu J, Benatar M. Treatment of ocular symptoms in myasthenia gravis. Neurology 2008;71:1335-41.
54. Kupersmith MJ, Moster M, Bhuiyan S, Warren F, Weinberg H. Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch Neurol 1996;53:802-4.
55. Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 2003;60:243-8.
56. Mee J, Paine M, Byrne E, King J, Reardon K, O'Day J. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol 2003;23:251-5.
57. Allen JA, Scala S, Jones HR. Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis. Muscle Nerve 2010;41:379-84.
58. Agius MA. Treatment of ocular myasthenia with corticosteroids: yes. Arch Neurol 2000;57:750-1.
59. Evoli A, Batocchi AP, Minisci C, Di Schino C, Tonali P. Therapeutic options in ocular myasthenia gravis. Neuromuscul Disord 2001;11:208-16.
60. Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993;94:379-87.
61. Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nature Review Rheumatol 2010;6:129-37.
62. Dalakas MC. Therapeutic approaches in patients with inflammatory myopathies. Semin Neurol 2003;23:199-206.
63. Hohlfeld R, Dalakas MC. Basic principles of immunotherapy for neurologic diseases. Semin Neurol 2003;23:121-32.
64. Mastaglia FL, Phillips BA, Zilko P. Treatment of inflammatory myopathies. Muscle Nerve 1997;20:651-64.
65. Mastaglia FL. Treatment of autoimmune inflammatory myopathies. Curr Opin Neurol 2000;13:507-9.
66. Dalakas MC. Therapy for immune-mediated inflammatory myopathies. In: Johnson RT, Griffin JW, McArthur JC7th ed. 7. Philadelphia: Mosby; 2006. p. 396-402.
67. Dalakas MC. Polymyositis, dermatomyositis and inclusion body myositis. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editor. Harrison’s Principles of Internal Medicine. 15th ed. New York: McGraw-Hill; 2001. p. 2524-9.
68. Bolosiu HD, Man L, Rednic S. The effect of methylprednisolone pulse therapy in polymyositis/ dermatomyositis. Adv Exp Med Biol 1999;455:349-57.
69. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senécal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005;84:231-49.
70. Hench PS, Kendall EC, Slocumb CH, Polley HF. The effects of a hormone of the adrenal cortex (17-hydroxy-11-dehydorcorticosterone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 1949;24:181-97.
71. Hench PS, Kendall EC, Slocumb CH, Polley HF. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Intern Med (Chic) 1950;85:545-666.
73. Frey BM, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 1990;19:126-46.
74. Schimmer BP, Funder JW. ACTH, Adrenal Steroids, and Pharmacology of the Adrenal Cortex. In: Brunton L, Chabner BA, Knollman B, editor. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill Education; 2011. p. 1209-36.